Clinical Trials Search Results
Clinical trials provide an important step in discovering new treatments. You can browse the list of current clinical trials below to learn more.
A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Sponsor: Shanghai Henlius Biotech
D3250R00107 – BURAN: Effects of Benralizumab in Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters
The aim of this study is to learn more about the drug called benralizumab (Fasenra®) and to better understand how it works in the treatment of severe eosinophilic asthma.
Identification of Immunological Host Defense Mechanisms Against Nontuberculous Mycobacteria: A pilot Study to Measure Immune Response in Patients with and without Nontuberculous Mycobacterial (NTM) Infection
The purpose of this study is to gain insight into the factors that contribute to protection against NTM. It is hoped that information collected from this study will lead to new treatment options to improve outcomes of patients infected with NTM.
IRB #: 1085
Multicenter randomized pragmatic clinical trial comparing two-versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease
The purpose of this study is to compare the effectiveness and tolerability of a 2-study drug treatment regimen and a 3-study drug treatment regimen in subjects who have recently been diagnosed with pulmonary (lung) disease caused by Mycobacterium avium complex (MAC).
The purpose of the program is to identify a group of people who are interested in receiving information about research studies focused on bronchiectasis and/or non-tuberculosis mycobacteria (NTM) and possibly participating in these research studies.
Sponsor: COPD Foundation
The goal of the Patient Registry is to collect data on individuals with cystic fibrosis (CF) to better understand the illness and ultimately improve the care and survival of those with CF.
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: Panbela Therapeutics
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors (Cohorts for Prostate Cancer and Melanoma open)
Sponsor: Seagen Inc
Symphony-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma
Sponsor: Epizyme, Inc
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Sponsor: Karyopharm Therapeutics Inc
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: Adlai Nortye Biopharma Co
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Daiichi Sankyo, Inc
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Sponsor: Bristol-Myers Squibb
A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy
RVN-301 – A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacology of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough.
Sponsor: Renovion, Inc.
MACrO2 – A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with treatment-Refractory Mycobacterium avium Complex Lung Disease – Protocol EBO-301
Sponsor: AN2 Therapeutics
1397-0012 – A randomized, double-blind, placebo-controlled, parallel-group, dose-finding study evaluating efficacy, safety, and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis
Development of a nontuberculous mycobaterial pulmonary disease symptom scale
INS1007-211 – A single-blind, placebo-controlled, parallel-group study to assess the safety, tolerability and pharmacokinetics of brensocatib administered once daily for 4 weeks in subjects with cystic fibrosis
Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease
PTK0796-NTM-20203 – A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc)